retatrutide efficacy clinical trials Today, we shared new data from two Phase 3 of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v VisualAbstract: Retatrutide reduces body weight

When timer sounds, wash hands, prep site, draw medication, inject, log

S., S., et al

This pilot will be a huge social and healthcare experiment

Tesofensine has been reported to produce roughly twice the weight loss of some currently approved obesity drugs

Some researchers have pointed out that the common digestive adverse reactions of the drug (diarrhea, vomiting, loss of appetite) may be contributing to their supposed weight loss success and are not ideal ways to support metabolic health at its foundation

Medical Review Reviewed by Sarah Thompson, RD, CSOWM (Certified Specialist in Obesity and Weight Management) 12+ years experience with weight loss medication protocols